Short answer
Dexcom (DXCM) filed an 8-K current report with the SEC on May 15, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item 8.01 (Other Events). Long-range targets use non-GAAP Organic Revenue growth, Gross Profit Margin, Operating Margin, and Adjusted EBITDA Margin.
Dexcom 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- Long-range targets use non-GAAP Organic Revenue growth, Gross Profit Margin, Operating Margin, and Adjusted EBITDA Margin
- Dexcom cannot reconcile these targets because influencing items remain uncertain or outside management control
- Investors should rely on Exhibit 99.1 for metric definitions and assess targets with limited GAAP comparability
Item 8.01 · Other Events
- New $1.0 billion share repurchase authorization runs through June 30, 2027
- Existing program terminated with $250.0 million remaining authorization
- Potentially supports per-share metrics and signals capital-return confidence, but actual repurchases remain discretionary
- Purchases may occur through open-market, private transactions, or Rule 10b5-1 trading plans
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Dexcom 8-K filings
Get the next DXCM 8-K as it lands
Follow DXCM for push alerts, or ask the research agent what this filing means.